ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+25.71%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$123M
AUM Growth
+$123M
(+4.1%)
Cap. Flow
-$14.4M
Cap. Flow
% of AUM
-11.67%
Top 10 Holdings %
Top 10 Hldgs %
61.58%
Holding
49
New
16
Increased
11
Reduced
12
Closed
7
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$3.14M |
| 2 |
Vaxcyte
PCVX
|
$2.86M |
| 3 |
Insmed
INSM
|
$2.58M |
| 4 |
CMPS
Compass Pathways
CMPS
|
$2.43M |
| 5 |
MREO
Mereo BioPharma
MREO
|
$2.4M |
Top Sells
| 1 |
Ocular Therapeutix
OCUL
|
$13.8M |
| 2 |
Praxis Precision Medicines
PRAX
|
$6.15M |
| 3 |
Dyne Therapeutics
DYN
|
$5.97M |
| 4 |
Sarepta Therapeutics
SRPT
|
$4.35M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$3.39M |
Sector Composition
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vaxcyte
PCVX
$4B
| $15.5M | 12.53% | 135,400 +25,000 | +23% | +$2.86M |
|
|
2
Ocular Therapeutix
OCUL
$2.12B
| $10.4M | 8.39% | 1,190,071 -1,581,059 | -57% | -$13.8M |
|
3
Tourmaline Bio
TRML
$601M
| $8.54M | 6.92% | 332,095 +62,481 | +23% | +$1.61M |
|
|
4
Insmed
INSM
$28.8B
| $7.85M | 6.36% | 107,500 +35,400 | +49% | +$2.58M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $7.57M | 6.13% | 296,368 -101,330 | -25% | -$2.59M |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $6.73M | 5.45% | 131,700 -3,441 | -3% | -$176K |
|
7
Arcellx
ACLX
$3.85B
| $5.19M | 4.2% | 62,100 +19,900 | +47% | +$1.66M |
|
|
MREO
8
Mereo BioPharma
MREO
$272M
| $5.18M | 4.2% | 1,260,700 +583,700 | +86% | +$2.4M |
|
9
Revolution Medicines
RVMD
$7.1B
| $4.9M | 3.97% | 108,000 -25,000 | -19% | -$1.13M |
|
10
Taysha Gene Therapies
TSHA
$797M
| $4.26M | 3.45% | 2,118,992 -211,945 | -9% | -$426K |
|
11
Terns Pharmaceuticals
TERN
$609M
| $4.06M | 3.29% | 487,000 +117,720 | +32% | +$982K |
|
12
Kura Oncology
KURA
$686M
| $3.85M | 3.12% | 197,000 +34,000 | +21% | +$664K |
|
|
WHWK
13
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $3.81M | 3.09% | 1,849,402 | – | – |
|
14
Rocket Pharmaceuticals
RCKT
$354M
| $3.51M | 2.84% | 190,000 -60,370 | -24% | -$1.12M |
|
|
15
Praxis Precision Medicines
PRAX
$958M
| $3.31M | 2.68% | 57,500 -106,931 | -65% | -$6.15M |
|
16
argenx
ARGX
$43.6B
| $3.2M | 2.59% | 5,900 +1,900 | +48% | +$1.03M |
|
|
17
Ascendis Pharma
ASND
$11.8B
| $3.14M | 2.54% | +21,000 | New | +$3.14M |
|
|
CMPS
18
Compass Pathways
CMPS
$424M
| $2.43M | 1.97% | +386,500 | New | +$2.43M |
|
19
Mersana Therapeutics
MRSN
$36.5M
| $2.27M | 1.84% | 1,200,000 -463,000 | -28% | -$875K |
|
|
BBOT
20
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $1.89M | 1.53% | 180,945 +3,109 | +2% | +$32.5K |
|
|
SLRN
21
DELISTED
ACELYRIN
SLRN
| $1.79M | 1.45% | +364,000 | New | +$1.79M |
|
22
Edgewise Therapeutics
EWTX
$1.51B
| $1.68M | 1.36% | +63,000 | New | +$1.68M |
|
|
23
Dyne Therapeutics
DYN
$1.92B
| $1.66M | 1.34% | 46,200 -166,300 | -78% | -$5.97M |
|
24
Gilead Sciences
GILD
$140B
| $1.63M | 1.32% | +19,500 | New | +$1.63M |
|
25
Ultragenyx Pharmaceutical
RARE
$2.89B
| $1.39M | 1.13% | +25,100 | New | +$1.39M |
|